Articles by Craig H. Moskowitz, MD

Combining ctDNA and modern imaging with novel therapeutics may help determine subsets of patients who are eligible to receive reduced treatment courses.

As part of our coverage of the ASH Annual Meeting, we are discussing novel agents and strategies for relapsed/refractory Hodgkin lymphoma.